Effects of PPAR-α agonist and IGF-1 on estrogen sulfotransferase in human vascular endothelial and smooth muscle cells

Molecular Medicine Reports

Volumn 8, Issue 1, 2013, Pages 133-139

  Li, Yintao ^a   Xu, Yali ^a,b   Li, Xiaobo ^a   Qin, Yejun ^b   Hu, Renming ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Estrogen sulfotransferase; Insulin like growth factor 1; Peroxisome proliferator activated receptor

Indexed keywords

ESTRADIOL; ESTRADIOL SULFATE; ESTROGEN SULFOTRANSFERASE; LUCIFERASE; PIRINIXIC ACID; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; INCUBATION TIME; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; SULFATION; UMBILICAL ARTERY; UMBILICAL CORD; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ENZYME ACTIVATION; GENE EXPRESSION; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PPAR ALPHA; PROMOTER REGIONS, GENETIC; PYRIMIDINES; RNA, MESSENGER; SULFOTRANSFERASES;

EID: 84878938320     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1483     Document Type: Article

References (29)

1. Nofer JR: Estrogens and atherosclerosis: insights from animal models and cell systems. J Mol Endocrinol 48: R13-R29, 2012.
2. Ishibashi H, Suzuki T, Suzuki S, et al: Estrogen inhibits cell proliferation through in situ production in human thymoma. Clin Cancer Res 11: 6495-6504, 2005. (Pubitemid 41338987)
3. Xu Y, Liu X, Guo F, et al: Effect of estrogen sulfation by SULT1E1 and PAPSS on the development of estrogen-dependent cancers. Cancer Sci 103: 1000-1009, 2012.
4. Tong MH, Jiang H, Liu P, Lawson JA, Brass LF and Song WC: Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med 11: 153-159, 2005. (Pubitemid 40321350)
5. Wada T, Ihunnah CA, Gao J, et al: Estrogen sulfotransferase inhibits adipocyte differentiation. Mol Endocrinol 25: 1612-1623, 2011.
6. Gong H, Jarzynka MJ, Cole TJ, et al: Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res 68: 7386-7393, 2008.
7. Kodama S, Hosseinpour F, Goldstein JA and Negishi M: Liganded pregnane X receptor represses the human sulfotransferase SULT1E1 promoter through disrupting its chromatin structure. Nucleic Acids Res 39: 8392-8403, 2011.
8. Fruchart JC: Peroxisome proliferator-activated receptor-alpha (PPA Ralpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205: 1-8, 2009.
9. Hennuyer N, Tailleux A, Torpier G, et al: PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 25: 1897-1902, 2005. (Pubitemid 41243460)
10. Srivastava RA: Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis- susceptible F(1)B hamsters. Atherosclerosis 214: 86-93, 2011.
11. Zahradka P, Yurkova N, Litchie B, Moon MC, Del Rizzo DF and Taylor CG: Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation. Mol Cell Biochem 246: 105-110, 2003. (Pubitemid 36798729)
12. Hamblin M, Chang L, Fan Y, Zhang J and Chen YE: PPARs and the cardiovascular system. Antioxid Redox Signal 11: 1415-1452, 2009.
13. Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA and Runge-Morris M: Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol Pharmacol 67: 1257-1267, 2005. (Pubitemid 40410426)
14. Higashi Y, Sukhanov S, Anwar A, Shai SY and Delafontaine P: IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab 21: 245-254, 2010.
15. Higashi Y, Sukhanov S, Anwar A, Shai SY and Delafontaine P: Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci 67: 626-639, 2012.
16. Han Y, Qi Y, Kang J, Li N, Tian X and Yan C: Nerve growth factor promotes formation of lumen-like structures in vitro through inducing apoptosis in human umbilical vein endothelial cells. Biochem Biophys Res Commun 366: 685-691, 2008.
17. Vadiveloo PK, Filonzi EL, Stanton HR and Hamilton JA: G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis 133: 61-69, 1997. (Pubitemid 27322118)
18. Yeong P, Ning Y, Xu Y, Li X and Yin L: Tryptase promotes human monocyte-derived macrophage foam cell formation by suppressing LXRalpha activation. Biochim Biophys Acta 1801: 567-576, 2010.
19. Wang X, Spandidos A, Wang H and Seed B: PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res 40: D1144-D1149, 2012.
20. Kushida A, Hattori K, Yamaguchi N, Kobayashi T, Date A and Tamura H: Sulfation of estradiol in human epidermal keratinocyte. Biol Pharm Bull 34: 1147-1151, 2011.
21. Xu Y, Yang X, Wang Z, et al: Estrogen sulfotransferase (SULT1E1) regulates inflammatory response and lipid metabolism of human endothelial cells via PPARgamma. Mol Cell Endocrinol 369: 140-149, 2013.
22. Lalloyer F, Wouters K, Baron M, et al: Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 31: 1573-1579, 2011.
23. Chinetti G, Lestavel S, Bocher V, et al: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53-58, 2001. (Pubitemid 32095642)
24. Gizard F, Nomiyama T, Zhao Y, et al: The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res 103: 1155-1163, 2008.
25. Plutzky J: The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res 108: 1002-1016, 2011.
26. Zoete V, Grosdidier A and Michielin O: Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771: 915-925, 2007. (Pubitemid 47208545)
27. Sukhanov S, Higashi Y, Shai SY, et al: Differential requirement for nitric oxide in IGF-1-induced anti-apoptotic, anti-oxidant and anti-atherosclerotic effects. FEBS Lett 585: 3065-3072, 2011.
28. Wang J, Razuvaev A, Folkersen L, et al: The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis 220: 102-109, 2012.
29. Delafontaine P, Song YH and Li Y: Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24: 435-444, 2004. (Pubitemid 38326135)